Circulating concentrations of soluble receptor for AGE are associated with age and AGER gene polymorphisms in children with newly diagnosed type 1 diabetes

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 1975-1981

  Salonen, Kirsi M ^a   Ryhänen, Samppa J ^a   Forbes, Josephine M ^b   Härkönen, Taina ^a   Ilonen, Jorma ^c,d   Laine, Antti Pekka ^c   Groop, Per Henrik ^a,e,f,g   Knip, Mikael ^a,e,h  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^h TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HLA DQ ANTIGEN; HLA DR ANTIGEN; SOLUBLE ADVANCED GLYCATION END PRODUCT RECEPTOR; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; HLA DR4 ANTIGEN; IMMUNOGLOBULIN RECEPTOR;

ADOLESCENT; AGE; AGER GENE; ALLELE; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; ETHNIC GROUP; FEMALE; FINNISH; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; GENETICS; HAPLOTYPE; INFANT; PHENOTYPE; PRESCHOOL CHILD;

ADOLESCENT; AGE FACTORS; ALLELES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; GENOTYPE; GLYCOSYLATION END PRODUCTS, ADVANCED; HAPLOTYPES; HLA-DR ANTIGENS; HLA-DR4 ANTIGEN; HUMANS; INFANT; MALE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC;

EID: 84903536479     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-3049     Document Type: Article

References (34)

1. Knip M, Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb Perspect Med 2012;2:a007690
2. Norris JM. Infant and childhood diet and type 1 diabetes risk: recent advances and prospects. Curr Diab Rep 2010;10:345-349
3. Henle T. Protein-bound advanced glycation endproducts (AGEs) as bioactive amino acid derivatives in foods. Amino Acids 2005;29:313-322 (Pubitemid 41813489)
4. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597-605 (Pubitemid 44199649)
5. Matsuoka T, Kajimoto Y, Watada H, et al. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest 1997;99:144-150 (Pubitemid 27058305)
6. Kaneto H, Fujii J, Myint T, et al. Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through the glycation reaction. Biochem J 1996;320:855- 863
7. Peppa M, He C, Hattori M, McEvoy R, Zheng F, Vlassara H. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 2003;52:1441-1448 (Pubitemid 36666199)
8. Beyan H, Riese H, Hawa MI, et al. Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. Diabetes 2012;61:1192-1198
9. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489- 497
10. Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003;198:1507-1515 (Pubitemid 37467165)
11. Sugaya K, Fukagawa T, Matsumoto K, et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 1994;23:408-419 (Pubitemid 24308262)
12. Damiani G, Campo I, Zorzetto M, et al. Proinflammatory variants of DRB1 and RAGE genes are associated with susceptibility to pediatric type 1 diabetes: a new hypothesis on the adaptive role of autoimmunity. Riv Biol 2007;100:285-304 (Pubitemid 350076201)
13. Forbes JM, Söderlund J, Yap FY, et al. Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia 2011;54:1032-1042
14. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, Grant PJ, Groop PH; Finn-Diane Study Group. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 2003;52:891-894 (Pubitemid 36323601)
15. Gaens KH, Ferreira I, van der Kallen CJ, et al. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 2009;94:5174-5180
16. Jang Y, Kim JY, Kang SM, et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 2007;56:199-205 (Pubitemid 46074066)
17. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-1109 (Pubitemid 36399105)
18. Yap FY, Kantharidis P, Coughlan MT, Slattery R, Forbes JM. Advanced glycation end products as environmental risk factors for the development of type 1 diabetes. Curr Drug Targets 2012;13:526-540
19. Chen Y, Yan SS, Colgan J, et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol 2004;173:1399-1405 (Pubitemid 38924321)
20. Harjutsalo V, Sjöberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008;371:1777-1782 (Pubitemid 351697953)
21. Harjutsalo V, Sund R, Knip M, Groop PH. Incidence of type 1 diabetes in Finland. JAMA 2013;310:427-428
22. Parkkola A, Härkönen T, Ryhänen SJ, Ilonen J, Knip M; Finnish Pediatric Diabetes Register. Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children. Diabetes Care 2013;36:348-354
23. Salonen KM, Ryhänen S, Härkönen T, Ilonen J, Knip M; Finnish Pediatric Diabetes Register. Autoantibodies against zinc transporter 8 are related to age, metabolic state and HLA DR genotype in children with newly diagnosed type 1 diabetes. Diabetes Metab Res Rev 2013;29:646-654
24. Kupila A, Muona P, Simell T, et al.; Juvenile Diabetes Research Foundation Centre for the Prevention of Type I Diabetes in Finland. Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia 2001;44:290-297 (Pubitemid 32234453)
25. World Health Organization Multicentre Growth Reference Study Group. WHO child growth standards: methods and development: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age [article online], 2006. Geneva, Switzerland, World Health Organization. Available from http://www.who.int/childgrowth/publications/technical-report- velocity/en. Accessed 15 March 2014
26. Wittkowski H, Hirono K, Ichida F, et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 2007;56:4174-4181 (Pubitemid 350262345)
27. Myles A, Viswanath V, Singh YP, Aggarwal A. Soluble receptor for advanced glycation end-products is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels. J Rheumatol 2011;38:1994-1999
28. Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009;11:R39
29. Skrha J Jr, Kalousová M, Svarcová J, et al. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012;120:277-281
30. Dettoraki A, Gil AP, Spiliotis BE. Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009;22:895-904
31. Nin JW, Ferreira I, Schalkwijk CG, et al.; EURODIAB Prospective Complications Study Group. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009;52:705-714
32. Chiavaroli V, D' Adamo E, Giannini C, et al. Serum levels of receptors for advanced glycation end products in normal-weight and obese children born small and large for gestational age. Diabetes Care 2012;35:1361-1363
33. Komulainen J, Kulmala P, Savola K, et al. Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 1999;22:1950-1955 (Pubitemid 30433970)
34. Osawa M, Yamamoto Y, Munesue S, et al. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochim Biophys Acta 2007;1770:1468-1474